Rheumatoid arthritis in the Kingdom of Saudi Arabia

References

1. ↵
   1. Almoallim HM,
   2. Alharbi LA

   (2014) Rheumatoid arthritis in Saudi Arabia. Saudi Med J 35:1442–1454.

   OpenUrl
2. ↵
   1. Wegner N,
   2. Lundberg K,
   3. Kinloch A,
   4. Fisher B,
   5. Malmström V,
   6. Feldmann M,
   7. et al.

   (2010) Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 233:34–54.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Silman AJ,
   2. MacGregor AJ,
   3. Thomson W,
   4. Holligan S,
   5. Carthy D,
   6. Farhan A,
   7. et al.

   (1993) Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 32:903–907.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   1. Lundström E,
   2. Källberg H,
   3. Alfredsson L,
   4. Klareskog L,
   5. Padyukov L

   (2009) Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. Arthritis Rheum 60:1597–1603.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Musculoskeletal screening examination: GALS video. Arthritis Research UK. [Accessed 2015 April 15]

   , Available from:http://www.arthritisresearchuk.org/health-professionals-and-students/video-resources/rems/gals-screening-examination.aspx.
6. ↵
   1. Doherty M,
   2. Dacre J,
   3. Dieppe P,
   4. Snaith M

   (1992) The ‘GALS’ locomotor screen. Ann Rheum Dis 51:1165–1169.

   OpenUrlAbstract/FREE Full Text
7. ↵
   1. Demoruelle MK,
   2. Parish MC,
   3. Derber LA,
   4. Kolfenbach JR,
   5. Hughes-Austin JM,
   6. Weisman MH,
   7. et al.

   (2013) Performance of anti-cyclic citrullinated Peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease. Arthritis Rheum 65:2243–2252.

   OpenUrlCrossRefPubMed
8. ↵
   1. Mathews RJ,
   2. Robinson JI,
   3. Battellino M,
   4. Wong C,
   5. Taylor JC

   (2014) Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), et al. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis 73:1202–1210.

   OpenUrlAbstract/FREE Full Text
9. ↵
   1. Hazlewood GS,
   2. Akhavan P,
   3. Schieir O,
   4. Marshall D,
   5. Tomlinson G,
   6. Bykerk V,
   7. et al.

   (2014) Adding a “GRADE” to the quality appraisal of rheumatoid arthritis guidelines identifies limitations beyond AGREE-II. J Clin Epidemiol 67:1274–1285.

   OpenUrlCrossRefPubMed
10. ↵
    1. Emery P,
    2. Burmester GR,
    3. Bykerk VP,
    4. Combe BG,
    5. Furst DE,
    6. Barré E,
    7. et al.

    (2015) Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74:19–26.

    OpenUrlAbstract/FREE Full Text
11. ↵
    1. Tanaka Y,
    2. Hirata S

    (2014) Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis. Drugs 74:2129–2139.

    OpenUrlCrossRefPubMed
12. ↵
    1. O’Dell JR,
    2. Curtis JR,
    3. Mikuls TR,
    4. Cofield SS,
    5. Bridges SL Jr.,
    6. Ranganath VK,
    7. et al.

    (2013) Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis Rheum 65:1985–1994.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Klarenbeek NB,
    2. Güler-Yüksel M,
    3. van der Kooij SM,
    4. Han KH,
    5. Ronday HK,
    6. Kerstens PJ,
    7. et al.

    (2011) The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 70:1039–1046.

    OpenUrlAbstract/FREE Full Text